Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial
Abstract Endometrial cancers are characterized by frequent alterations in the PI3K-AKT-mTor, IGF1 and DNA repair signaling pathways. Concomitant inhibition of these pathways was warranted. ENDOLA phase I/II trial (NCT02755844) was designed to assess the safety/efficacy of the triplet combination of...
Sparad:
| Huvudupphov: | , , , , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Nature Portfolio
2025-02-01
|
| Serie: | Nature Communications |
| Länkar: | https://doi.org/10.1038/s41467-025-56914-7 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|